Squarepoint Ops LLC Boosts Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Squarepoint Ops LLC boosted its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 38.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 111,705 shares of the biopharmaceutical company's stock after purchasing an additional 30,842 shares during the quarter. Squarepoint Ops LLC owned about 0.09% of Catalyst Pharmaceuticals worth $2,331,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of CPRX. Steward Partners Investment Advisory LLC bought a new position in shares of Catalyst Pharmaceuticals in the fourth quarter valued at approximately $27,000. Farther Finance Advisors LLC raised its position in Catalyst Pharmaceuticals by 125.1% in the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock valued at $56,000 after buying an additional 1,495 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new position in Catalyst Pharmaceuticals during the 4th quarter valued at $65,000. KBC Group NV boosted its holdings in Catalyst Pharmaceuticals by 48.8% during the 4th quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company's stock worth $98,000 after acquiring an additional 1,542 shares during the last quarter. Finally, Quarry LP purchased a new position in Catalyst Pharmaceuticals during the 4th quarter worth $104,000. Institutional investors and hedge funds own 79.22% of the company's stock.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other news, insider Gary Ingenito sold 44,904 shares of the company's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total transaction of $991,929.36. Following the transaction, the insider now owns 68,873 shares of the company's stock, valued at $1,521,404.57. This represents a 39.47% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Brian Elsbernd sold 62,975 shares of Catalyst Pharmaceuticals stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the completion of the sale, the insider now directly owns 188,564 shares of the company's stock, valued at approximately $4,333,200.72. This trade represents a 25.04% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 351,879 shares of company stock valued at $8,214,815. Company insiders own 10.40% of the company's stock.

Catalyst Pharmaceuticals Trading Up 1.3%

Shares of NASDAQ:CPRX traded up $0.31 during mid-day trading on Friday, reaching $24.89. The company had a trading volume of 2,081,400 shares, compared to its average volume of 1,108,593. Catalyst Pharmaceuticals, Inc. has a one year low of $14.75 and a one year high of $26.16. The company's 50-day moving average price is $23.57 and its 200-day moving average price is $22.61. The firm has a market cap of $3.04 billion, a price-to-earnings ratio of 21.09, a PEG ratio of 3.31 and a beta of 0.70.

Wall Street Analyst Weigh In

Several brokerages have recently commented on CPRX. Stephens reiterated an "overweight" rating and issued a $33.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. Robert W. Baird boosted their target price on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a research note on Monday, March 3rd. HC Wainwright reaffirmed a "buy" rating and issued a $35.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Baird R W raised Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Monday, February 3rd. Finally, Wall Street Zen upgraded Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, February 28th. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Catalyst Pharmaceuticals has a consensus rating of "Buy" and an average price target of $32.29.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.